New research sheds light on childhood neuromuscular disease

A study by scientists at the Motor Neuron Center at Columbia University Medical Center suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from problems in the motor circuits that coordinate muscle movement. Previously, researchers thought that motor neurons or muscle cells were responsible.

In a second study, researchers at the Motor Neuron Center identified the molecular pathway in SMA that leads to problems with motor function. Findings from the studies could lead to therapies for the debilitating and often fatal neuromuscular disease.

"To our knowledge, this is the first clear demonstration that defects in the function of a neuronal circuit are the cause of a neurological disease," Dr. Brian McCabe, assistant professor of pathology and cell biology, said about the first study.

Both studies were published online Oct. 11 in the journal Cell.

SMA is a hereditary neuromuscular disease characterized by and weakness. There is no treatment for SMA, which is estimated to affect as many as 10,000 to 25,000 children and adults in the United States and is the leading genetic cause of death in infants.

Based on the findings of McCabe and his colleagues, the SMA Clinical Research Center at CUMC launched a clinical trial last July of a potassium channel blocker called dalfampridine for the treatment of patients with SMA. The drug is currently marketed under the brand name Ampyra for multiple sclerosis. "This drug is unlikely to be a cure for SMA, but we hope it will benefit patient symptoms," McCabe said.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments